Summary Mitozolomide and its decomposition product MCTIC were found to be more cytotoxic to BE colon carcinoma cells in vitro than to 
8-carbamoyl-3-(2-chloroethyl)imidazol5, 1-dI-l, 2, 3, 5-tetrazin-4(3H)-one (mitozolomide) is a newly synthesised heterocyclic compound which demonstrates curative action against a wide variety of murine tumours . Chemical studies have suggested that mitozolomide cleaves to 5-(3-(2-chloroethyl)-triazen-1-yl)-imidazo-4-carboxamide (MCTIC) . We have recently shown that mitozolomide, MCTIC and 1-(2-chloroethyl)-1-nitrosourea (CNU), react with the DNA of L1210 cells and produce a similar quantity of DNA interstrand crosslinks (Gibson et al., 1984a) . Both MCTIC and CNU, and probably mitozolomide, decompose to form a 2-chloroethyldiazonium species Shealy et al., 1975; Weinkam & Lin, 1979) which is thought to be responsible for the initial alkylation and subsequent crosslinking of DNA (Kohn, 1977) .
Certain human cells are known to differ in their ability to repair adenovirus which has been damaged by in vitro treatment with MNNG (Day et al., 1980a) . Cells which reactivate the virus and support its replication have been designated Mer+, and cells deficient in virus reactivation Mer- (Day et al., 1980a) . Mer+ cells were recently shown to be more efficient at the removal of 06-methylguanine Correspondence: L.C. Erickson. Received 14 August 1984; and revised form 29 March 1985. lesions in their DNA, whereas Mer-cells did not repair this lesion (Day et al., 1980b) . It has recently been shown that a clear correlation exists between the Mer phenotype and DNA interstrand crosslinking in human cells exposed to CNU (Erickson et al., 1980) . In Mer-cells CNU produced consistently higher levels of interstrand crosslinking than in Mer+ cells. Little or no DNA interstrand crosslinks were observed in the Mer+ cells after exposure to CNU. We have also shown that a similar correlation exists between the Mer phenotype and DNA interstrand crosslinking in normal and SV-40 transformed human cells exposed to either mitozolomide or MCTIC (Gibson et al., 1984b) .
Recent work has shown that pretreatment of Mer+ cells with the methylating agent MNNG inactivates the enzymatic activity responsible for the removal of 06-alkylguanine lesions, and thus allows the formation of CNU induced DNA interstrand crosslinks (Zlotogorski & Erickson, 1983) . In addition this pretreatment was found to greatly enhance the killing of Mer+ cells by CNU (Zlotogorski & Erickson, 1983) . Pretreatment of Mer-cells, however, had little effect on either the cell killing of CNU or its ability to induce a greater quantity of DNA interstrand crosslinks (Zlotogorski & Erickson, 1983) . These data agree with the hypothesis that CNU induced crosslinks are produced in DNA via chloroethyl monoadduct formation at the 06-position of guanine, followed by the completion of an interstrand crosslink in a delayed reaction with the opposite DNA strand (Kohn, 1977) . The formation of such crosslinks by the chloroethylnitrosoureas has been prevented by a guanine-06-alkyltransferase activity purified from an E coli cell extract (Robins et al., 1983) . Furthermore Brent has recently shown that DNA crosslink formation, induced by the chloroethylnitrosoureas, is inhibited by an extract from cultured human leukaemic lymphoblasts (Brent, 1984) . This activity which inhibits crosslink formation copurifies with 06-methylguanine DNA methyltransferase and shows similar kinetic properties (Brent, 1984) . Thus the same enzymatic activity may be responsible for the removal of methyl and chloroethyl monoadducts from the 06_ position of guanine.
In the present study we have examined the effects of MNNG pretreatment on the mitozolomide and MCTIC induced DNA interstrand crosslinking in two human colon carcinoma cell lines, one determined to be Mer+ (HT-29) and the other Mer-(BE) (Day et al., 1980a Colony forming assays HT-29 and BE cells were seeded at 0.1, 0.3, 1, 3, and 10 x 103 cells per 25 cm2 plastic flasks (Costar, Cambridge, Ma). The flasks were incubated for 12-20 h to allow the cells to attach to the bottom of the flask. The cells were then exposed to one of the following drug protocols: control cells received no drugs, mitozolomide or MCTIC only for 2 h, MNNG only for 1 h, MNNG for 1 h followed by a medium change and mitozolomide or MCTIC for an additional 2 h. After 10 days of incubation in fresh media, the flasks were rinsed with Hanks balanced salt solution, fixed with methanol, and then stained with a solution containing 1 ml methylene blue, 1 ml 0.15 M Na2HP04 and 1 ml 0.15 M KH2PO4 diluted to 50 ml with distilled water. Colonies were counted and the observed plating efficiencies were 67% for HT-29 cells and 40% for BE cells.
Assay of DNA damage by alkaline elution The basic principles involved in the detection of DNA damage by the alkaline elution assay have been published and the methodology has recently been reviewed in detail (Kohn et al., 1981) . In order to accommodate the quantity of MNNG induced single strand breaks the modification of Zlotogorski and Erickson (1983) was followed. Cells that were pretreated with MNNG were only irradiated with 1.5Gy of X-ray. This was done as 2pM MNNG was found to cause a similar quantity of DNA strand breaks as that produced by 1.5Gy of X-ray (data not shown). Thus MNNG pretreatment plus The appearance of DNA-DNA interstrand crosslinks was examined in both BE (upper panels) and HT-29 (lower panels) treated with mitozolomide ( Figure 2 ) or MCTIC (Figure 3) . In addition the effect of MNNG pretreatment on the ability of either mitozolomide or MCTIC to induce DNA-DNA interstrand crosslinking was determined (Figures 2 and 3 , right hand side panels). Both mitozolomide and MCTIC induced DNA (Gibson et aL, 1984b Figure 4 Alkaline elution assays to test for the formation of DNA-protein crosslinks after mitozolomide treatment on BE (a) and (b) colon carcinoma cells. Cells were treated with drug concentrations as indicated for 2h at 37°C and then allowed to incubate for 6h in drug free medium. Prior to alkaline elution all cells were irradiated with 30Gy of y-irradiation from a "37Cs source. These profiles are taken from one experiment and are representative of at least two other independent experiments. (0) 30.0Gy; (A) 12.5jm+30Gy; (U) 25pM+3OGy; (*) 50uM+30Gy; (O) l00pM+3OGy; (V) 200iM+3OGy; (O) 300 uM + 30 Gy. similar in both cell lines. This is in good agreement with data previously obtained for CNU (Zlotogorski & Erickson, 1984) .
Discussion
We have previously shown that mitozolomide and its decomposition product MCTIC were able to induce DNA interstrand crosslinks in an SV-40 transformed human embryonic cell line which was deficient (Mer-) in the ability to repair 06_ alkylguanine lesions (Gibson et al., 1984b) . We also showed that in a normal human embryonic cell line (Mer+) proficient in the repair of 06-alkylguanine lesions no DNA interstrand crosslinking was induced by mitozolomide and MCTIC (Gibson et al., 1984b) . From these data we hypothesised that mitozolomide may chloroethylate DNA, in particular at the 06 position of guanine which then results in a DNA crosslink by a similar mechanism to that previously proposed for the chloroethylnitrosoureas (Kohn, 1977) .
In this study with mitozolomide a similar series of findings has been presented. Namely that Mercells (BE) The differences observed between the HT-29 and BE cells, and between HT-29 cells with or without MNNG pretreatment, may be a consequence of impaired drug uptake. However, the similarity between the DNA-protein crosslinking levels observed in HT-29 and BE cells at equimolar concentrations suggests that intracellular drug reactivity is equivalent. Furthermore no difference in the DNA-protein crosslinking induced by mitozolomide was found with or without MNNG pretreatment (data not shown). These results are in good agreement with those obtained by Zlotogorski and Erickson(1984) with the chloroethylnitrosourea CNU.
Two mechanisms by which MNNG may inactivate the repair of 06-alkylguanine lesions have been proposed (Zlotogorski & Erickson, 1983; 1984) : MNNG may react directly with the repair protein thus inactivating it, or MNNG may directly alkylate the DNA, and then the protein which reacts with the alkylated guanine in a stoichiometric fashion is simply depleted. The evidence for and against both these mechanisms has been discussed in detail elsewhere (Zlotogorski & Erickson, 1983; 1984) and will not be elaborated upon here.
Chemical studies have shown that mitozolomide cleaves under physiological conditions to produce the monochloroethyltriazene MCTIC . Thus the ability of MCTIC to mimic the results of mitozolomide in this and numerous other studies (Gibson et al., 1984a, b; Horgan et al., 1983) , strongly suggests that this decomposition pathway is important for the pharmacological expression of mitozolomide. In this study we have shown that Mer+ cells which are proficient in the repair of 06-methylguanine lesions do not allow the formation of DNA interstrand crosslinking by chloroethylating agents such as mitozolomide. Pretreatment of these cells with MNNG, conditions which inhibit the 06-methylguanine transferase activity, allows the formation of mitozolomide induced DNA interstrand crosslinking in Mer+ cells. The results presented here strengthen our hypothesis that mitozolomide induced crosslinks probably arise after an initial alkylation at the 06_ position of guanine residues in DNA. In addition the enzymatic activity responsible for repairing 06_ methylguanine adducts in DNA would also appear to repair 06-chloroethylguanine adducts.
In conclusion the presence of a DNA repair system capable of repairing lesions at the 06_ position of guanine may make tumour cells resistant to treatment with mitozolomide or MCTIC. However, pretreatment with agents that methylate the 06-position of guanine, conditions which can inhibit this repair activity, may be used to sensitize tumour cells resistant to treatment with mitozolomide or MCTIC. The high carcinogenic potential of MNNG exposure suggests that this protocol will have limited applicability in vivo. However, recent experiments with the clinically used DNA methylating agent, streptozotocin, suggests that pretreatment with streptozotocin to sensitise human tumours to chloroethylating agents may have in vivo applicability (Erickson and Barnes; Gibson, Barnes and Erickson, in preparation) .
